Sensus Healthcare's (SRTS) Sell (D) Rating Reaffirmed at Weiss Ratings

Key Points

• Sensus Healthcare (NASDAQ:SRTS) has had its "sell" rating reaffirmed by Weiss Ratings, indicating a negative outlook from the analysts.
• Despite recent buy ratings from some analysts, the stock’s consensus price target is currently at $8.00, with its shares trading around $3.45, reflecting a significant decline.
• The company reported a negative earnings per share of ($0.06) last quarter, missing analysts' expectations and indicating ongoing financial struggles.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report)'s stock had its "sell (d)" rating restated by stock analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Other research analysts have also recently issued research reports about the stock. Lake Street Capital reduced their target price on shares of Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating for the company in a report on Friday, August 8th. HC Wainwright reduced their target price on shares of Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. Zacks Research cut shares of Sensus Healthcare from a "hold" rating to a "strong sell" rating in a report on Tuesday, September 23rd. Finally, Wall Street Zen cut shares of Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Sunday, June 22nd. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $8.00.

Sensus Healthcare Trading Down 2.8%

NASDAQ SRTS opened at $3.45 on Wednesday. The company has a fifty day simple moving average of $3.52 and a two-hundred day simple moving average of $4.29. The stock has a market cap of $56.72 million, a P/E ratio of -57.50 and a beta of 1.38. Sensus Healthcare has a 12-month low of $3.03 and a 12-month high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.07). The company had revenue of $7.32 million during the quarter, compared to analysts' expectations of $9.30 million. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%. As a group, sell-side analysts forecast that Sensus Healthcare will post 0.32 earnings per share for the current year.

Institutional Trading of Sensus Healthcare

Several institutional investors have recently modified their holdings of the stock. Kingstone Capital Partners Texas LLC acquired a new stake in shares of Sensus Healthcare in the second quarter valued at about $3,170,000. Acadian Asset Management LLC grew its position in shares of Sensus Healthcare by 35.3% in the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company's stock valued at $2,225,000 after purchasing an additional 122,746 shares during the period. Divisadero Street Capital Management LP grew its position in shares of Sensus Healthcare by 459.4% in the second quarter. Divisadero Street Capital Management LP now owns 324,673 shares of the company's stock valued at $1,539,000 after purchasing an additional 266,635 shares during the period. Geode Capital Management LLC grew its position in shares of Sensus Healthcare by 2.5% in the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company's stock valued at $730,000 after purchasing an additional 3,766 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Sensus Healthcare by 3.9% in the first quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock valued at $672,000 after purchasing an additional 5,289 shares during the period. Institutional investors and hedge funds own 25.30% of the company's stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.